OverviewSuggest Edit

DURECT began life in 1998 dedicated to exploiting the benefits of enhanced drug delivery. Our goal was to optimize the physical, pharmacokinetic, and pharmacodynamic properties of approved active agents in ways that would solve significant clinical problems. In recent years, we have built upon this significant legacy, expanding our reach to encompass the development of a family of endogenous molecules that are entirely new to pharmaceutical research and that show remarkable promise in a number of important therapeutic areas.

Whether taking aim at improved drug formulations or bringing to market therapies based on completely novel molecules and avenues of research, the men and women of DURECT strive to fulfill a fundamental promise to patients, physicians, corporate partners, and investors: create best-in-class pharmaceutical products with enduring value—measured most directly by their potential to make real, palpable differences in the lives of those who need them.

TypePublic
HQCupertino, CA, US
Websitedurect.com
Employee Ratings2.6

Latest Updates

Employees (est.) (Feb 2020)90(+3%)
Revenue (FY, 2020)$30.1 M(+2%)
Share Price (Jul 2021)$1.4

Key People/Management at Durect

James E. Brown

James E. Brown

President and Chief Executive Officer
David R. Hoffmann

David R. Hoffmann

Chairman of the Board
David J. Ellis

David J. Ellis

Vice President, Clinical Development
Terrence F. Blaschke

Terrence F. Blaschke

Director
Norman L. Sussman

Norman L. Sussman

Chief Medical Officer
Gail M. Farfel

Gail M. Farfel

Director
Show more

Durect Office Locations

Durect has an office in Cupertino
Cupertino, CA, US (HQ)
DURECT, 10260 Bubb Rd
Show all (1)

Durect Financials and Metrics

Durect Revenue

Embed Graph
View revenue for all periods
Durect's revenue was reported to be $30.11 m in FY, 2020
USD

Revenue (Q1, 2021)

2.2m

Gross profit (Q1, 2021)

1.9m

Gross profit margin (Q1, 2021), %

84.1%

Net income (Q1, 2021)

(10.1m)

EBIT (Q1, 2021)

(9.6m)

Market capitalization (16-Jul-2021)

307.0m

Closing stock price (16-Jul-2021)

1.4

Cash (31-Mar-2021)

57.5m

EV

270.4m
Durect's current market capitalization is $307 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

33.5m53.1m15.3m19.4m19.1m14.0m49.2m18.6m29.6m30.1m

Revenue growth, %

27%(1%)(27%)

Cost of goods sold

4.7m4.7m4.8m5.7m3.9m5.3m6.6m4.3m4.1m1.4m

Gross profit

28.8m48.4m10.5m13.7m15.2m8.7m42.5m14.3m25.4m28.7m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

8.9m11.2m7.8m2.7m3.6m5.4m29.4m31.6m34.9m21.3m

Accounts Receivable

3.4m2.2m2.3m2.1m2.2m1.2m2.4m1.8m2.3m940.0k

Prepaid Expenses

1.8m2.3m1.9m1.0m3.1m3.1m2.2m1.5m4.5m

Inventories

3.3m3.4m3.5m3.6m3.9m3.8m3.2m3.4m3.4m1.9m
USDQ2, 2011

Financial Leverage

7.3 x
Show all financial metrics

Durect Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Durect Online and Social Media Presence

Embed Graph

Durect News and Updates

Thinking about buying stock in Durect Corp, T2 Biosystems, Gevo Inc, BioNano Genomics, or Advanced Micro Devices?

NEW YORK, Feb. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DRRX, TTOO, GEVO, BNGO, and AMD. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Durect stock soars 34% after it gets FDA approval for surgical pain treatment

Shares of Durect Corp. gained 34.3% in premarket trading on Tuesday after the company said its drug, Posimer, had been approved by the Food and Drug Administration as a treatment for pain after a certain type of shoulder surgery. The drug is not an opioid. The company said that more than 600,000 ar…

UPDATE: Durect stock slides after FDA committee ends meeting with split vote on post-surgical pain treatment

Biopharmaceutical company Durect Corp.'s shares slid 12% in premarket trade Friday, after a U.S. Food and Drug Administration committee ended a meeting to review the company's Posimir treatment for post-surgical pain with a split vote, as six members voted to recommend the treatment and six voted a…

Biopharma Durect says FDA committee ended meeting with split vote on post-surgical pain treatment

Biopharmaceutical company Durect Corp. said Friday a U.S. Food and Drug Administration committee ended a meeting to review its Posimir treatment for post-surgical pain with a split vote, as six members voted to recommend the treatment and six voted against. The stock remained halted in premarket tr…

Biopharma Durect shares halted ahead of FDA committee meeting on post-surgical pain treatment

Shares of biopharmaceutical company Durect Corp. were halted Thursday, ahead of a U.S. Food and Drug Administration committee meeting to review Posimir, a treatment for post-surgical pain. The meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) will start at 8 a.m. Eas…

Durect Blogs

DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29

DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29 Content Import Thu, 07/22/2021 - 08:32 DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29 Jul 22, 2021 …

DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit

DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit Content Import Wed, 07/14/2021 - 16:32 DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit Jul 14, 2021 This release is a backfill from …

DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL)

New Data Further Supports DUR-928's Potential in Acute and Chronic as well as Moderate and Severe Liver Disease CUPERTINO, Calif. , June 23, 2021 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced the presentation of additional clinical data from a DUR-928 Phase 1b trial in

DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)

CUPERTINO, Calif. , June 9, 2021 /PRNewswire/ --  DURECT Corporation (Nasdaq: DRRX) today announced it will present two posters at the 2021 International Liver Conference (EASL)  to be held virtually June 23-26, 2021 .  The first poster will discuss additional efficacy signals from a Phase 1b

DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs

DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs Content Import Tue, 05/04/2021 - 16:10 DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs May 04, 2021 This release is a backfill fro…

DURECT Corporation to Announce First Quarter 2021 Financial Results and Provide Business Update on May 4

CUPERTINO, Calif. , April 27, 2021 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX) today announced that it will report its first quarter 2021 financial results and host a conference call after the market close on Tuesday, May 4, 2021 . Tuesday, May 4 @ 4:30pm Eastern Time   / 1:30 p.m.
Show more

Durect Frequently Asked Questions

  • Who are Durect key executives?

    Durect's key executives are James E. Brown, David R. Hoffmann and David J. Ellis.

  • How many employees does Durect have?

    Durect has 90 employees.

  • What is Durect revenue?

    Latest Durect annual revenue is $30.1 m.

  • What is Durect revenue per employee?

    Latest Durect revenue per employee is $334.6 k.

  • Who are Durect competitors?

    Competitors of Durect include BTG, Avid Bioservices and Recro Gainesville.

  • Where is Durect headquarters?

    Durect headquarters is located at DURECT, 10260 Bubb Rd, Cupertino.

  • Where are Durect offices?

    Durect has an office in Cupertino.

  • How many offices does Durect have?

    Durect has 1 office.